Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CAN-3110,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Batavia and Candel Partner to Accelerate Development of CAN-3110
Details : The partnership aims to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).
Brand Name : CAN-3110
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 21, 2024
Lead Product(s) : CAN-3110,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Inactivated polio vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Valneva
Deal Size : Undisclosed
Deal Type : Collaboration
Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development
Details : Under the terms of the agreement, Valneva will manufacture the sIPV vaccine for clinical trial purposes in its state-of-the-art GMP polio manufacturing facility operated under GAPIII[2] polio containment in Solna, Sweden, using Batavia’s process.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Inactivated polio vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Valneva
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VSV∆G-SARS-CoV-2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Collaboration
Details : By working with Batavia Biosciences, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines, including vaccines against a group of viruses that cause hemorrhagic fevers and other emerging viral...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 05, 2020
Lead Product(s) : VSV∆G-SARS-CoV-2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?